Vilma Fondevilla Tadalan-velasco, MD | |
80 Kirks Mill Ln, North East, MD 21901-1712 | |
(702) 430-8881 | |
Not Available |
Full Name | Vilma Fondevilla Tadalan-velasco |
---|---|
Gender | Female |
Speciality | Pediatrics |
Location | 80 Kirks Mill Ln, North East, Maryland |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194055871 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | D0014635 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Vilma Fondevilla Tadalan-velasco, MD 80 Kirks Mill Ln, North East, MD 21901-1712 Ph: (702) 430-8881 | Vilma Fondevilla Tadalan-velasco, MD 80 Kirks Mill Ln, North East, MD 21901-1712 Ph: (702) 430-8881 |
News Archive
NYU Langone Medical Center announced that it has reached a historic and unprecedented philanthropic milestone, raising $1 billion in less than four years.
Today, the Kaiser Family Foundation unveiled an innovative, online tool that allows users to learn quickly and easily about which global health interventions work. The Global Health Intervention Review (GHIR) compiles the latest information on the efficacy of key global health interventions, including the strength of the evidence, and presents the information in a variety of accessible formats. Users can view a comprehensive overview and a key findings table.
A new neuroimaging study at the Montreal Neurological Institute and Hospital at McGill University aims to ensure the highest quality of life for patients by assessing their cognitive skills before, during, and after brain tumour surgery. This is done by mapping the important functional brain areas surrounding the tumour in order to decrease the risks during surgery.
Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has entered into an exclusive, world-wide product development and distribution agreement with DiaSorin S.p.A. Under terms of the agreement, DiaSorin will utilize key Meridian technology to develop several infectious disease products for use on their LIAISON systems.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered what leads to two genes fusing together, a phenomenon that has been shown to cause prostate cancer to develop.
› Verified 2 days ago